December 8, 2012New England Journal of Medicine1,368 citationsOpen Access
Apixaban for Extended Treatment of Venous Thromboembolism
View Full Paper
Structured PICO
Does extended anticoagulation with apixaban reduce the risk of recurrent venous thromboembolism?
P
Population
Patients with venous thromboembolism requiring extended treatment
I
Intervention
Apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) for extended anticoagulation
O
Outcome
Recurrent venous thromboembolismhard clinical
Extended anticoagulation with apixaban (2.5 mg or 5 mg) effectively reduces recurrent VTE risk without increasing major bleeding.
Abstract
Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
Cite This Study
Agnelli et al. (2012) studied this question.